Search Results - "Lawrenz, T."

Systematic differences in electrochemical reduction of the structurally characterized anti-cancer platinum(IV) complexes [Pt{((p-HC6F4)NCH2)2}-(pyridine)2Cl2], [Pt{((p-HC6F4)NCH2)2}(pyridine)2(OH)2], and [Pt{((p-HC6F4)NCH2)2}(pyridine)2(OH)Cl] by Guo, Si-Xuan, Mason, Dayna N., Turland, Susan A., Lawrenz, Eric T., Kelly, Lance C., Fallon, Gary D., Gatehouse, Bryan M., Bond, Alan M., Deacon, Glen B., Battle, Andrew R., Hambley, Trevor W., Rainone, Silvina, Webster, Lorraine K., Cullinane, Carleen

“…The putative platinum(IV) anticancer drugs, [Pt{((R)NCH2)2}(py)2XY] (X,Y=Cl, R=p-HC6F4 (1a), C6F5 (1b); X,Y=OH, R=p-HC6F4 (2); X=Cl, Y=OH, R=p-HC6F4 (3), py =…”
Get full text

Insertion of CO2, CS2, and COS into Iron(II)−Hydride Bonds by Field, Leslie D, Lawrenz, Eric T, Shaw, Warren J, Turner, Peter

“…The reactions between cis-Fe(dmpe)2H2 (dmpe = Me2PCH2CH2PMe2) (1) or cis-Fe(PP3)H2 (PP3 = P(CH2CH2PMe2)3) (2) and carbon dioxide (CO2), carbon disulfide (CS2),…”
Get full text

Utility of endomyocardial biopsy guided by delayed enhancement areas on magnetic resonance imaging in the diagnosis of cardiac sarcoidosis by Borchert, B, Lawrenz, T, Bartelsmeier, M, Röthemeyer, S, Kuhn, H, Stellbrink, C

Get full text

Influence of pacemaker leads on the severity of tricuspid regurgitation after successful mitral valve edge to edge repair by Alsaad, M, Lawrenz, T, Marx, K, Stellbrink, C

“…Abstract Background After percutaneous mitral-valve edge-to-edge repair (MVER) for mitral regurgitation (MR) in patients with baseline tricuspid regurgitation…”
Get full text

Mid systolic septal deceleration in hypertrophic cardiomyopathy: clinical value and insights into the pathophysiology of outflow tract obstruction by tissue Doppler echocardiography by Breithardt, O-A, Beer, G, Stolle, B, Lieder, F, Franke, A, Lawrenz, T, Hanrath, P, Kuhn, H

“…Some patients may develop significant LVOT obstruction and an MSSD pattern during exercise despite a non-significant resting gradient. [...]the absence of an…”
Get full text

Is unsatisfactory outcome of alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy predictable? by Lawin, D, Stellbrink, C, Poudel, M R, Marx, K, Lawrenz, T

“…Abstract Background Alcohol septal ablation (ASA) has been introduced for left ventricular outflow tract gradient (LVOTG) reduction in patients with…”
Get full text

Efficacy and safety of alcohol septal ablation in adolescents and young adults with symptomatic hypertrophic obstructive cardiomyopathy by Lawin, D, Lawrenz, T, Radke, K, Stellbrink, C

“…Abstract Background In young patients suffering from hypertrophic obstructive cardiomyopathy (HOCM) surgical myectomy is still considered as the gold standard…”
Get full text

Long and short QT syndrome by Borchert, B, Lawrenz, T, Stellbrink, C

“…In the past decade molecular genetic analysis has greatly expanded our knowledge about inherited arrhythmogenic syndromes. The congenital long QT syndrome…”
Get full text

Gender-disparities in patients undergoing alcohol septal ablation for hypertrophic obstructive cardiomyopathy by Lawin, D, Stellbrink, C, Marx, K, Danielsmeier, N B, Poudel, M R, Lawrenz, T

“…Abstract Background Alcohol septal ablation (ASA) improves symptoms in patients with hypertrophic obstructive cardiomyopathy (HOCM) but gender-disparities have…”
Get full text

Modifying the properties of platinum(IV) complexes in order to increase biological effectiveness by Hambley, T.W., Battle, A.R., Deacon, G.B., Lawrenz, E.T., Fallon, G.D., Gatehouse, B.M., Webster, L.K., Rainone, S.

“…The preparation of a series of novel Pt(IV) complexes containing the anionic polyfluoroaryl ligands, 2,3,5,6-tetrafluorophenyl ( p-HC 6F 4),…”
Get full text

Effect of transcoronary ablation of septal hypertrophy on clinical outcome in hypertrophic obstructive cardiomyopathy associated with atrial fibrillation by Obergassel, L, Lawrenz, T, Gietzen, F H, Lieder, F, Leuner, C, Kuhn, H, Stellbrink, C

“…Relatively few reports on the clinical impact of atrial fibrillation (AF) in hypertrophic obstructive cardiomyopathy (HOCM) are available. The aims of our…”
Get full text

Cryoballoon ablation of atrial fibrillation in octogenarians: one year results from the Cryo Global Registry by Lawin, D, Stellbrink, C, Chun, K R J, Lim, H E, Obidigbo, V, Selma, J M, Peytchev, P, Nguyen, D Q, Foldesi, C, Lawrenz, T

“…Abstract Background A few studies have demonstrated the safety and efficacy of cryoballoon ablation (CBA) in elderly patients (≥75 years old) with atrial…”
Get full text

Efficacy and safety outcomes of early versus late cryoballoon ablation of atrial fibrillation - 24-months-results from the Cryo Global Registry by Lawin, D, Stellbrink, C, Chun, K R J, Li, C H, Kueffer, F, Selma, J, Oh, I Y, Herzet, J, Nitta, J, Chang, T Y, Lawrenz, T

“…Abstract Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Medtronic, Inc., Minneapolis, MN, USA Introduction…”
Get full text

Treatment of HOCM with massive hypertrophy: Is alcoholablation effective if septal diameter is greater than 30 mm? by Lawrenz, T., Schloesser, M., Stellbrink, C., Kuhn, H.

Get full text

Tash in young patients. Same effective? A retrospective study of 1200 patients by Schloesser, M., Lawrenz, T., Stellbrink, C., Kuhn, H.

Get full text

Endocardial radiofrequency ablation of septal hypertrophy. A new catheter-based modality of gradient reduction in hypertrophic obstructive cardiomyopathy by Lawrenz, T, Kuhn, H

“…Transcoronary alcohol ablation of septal hypertrophy (TASH) is a therapeutic catheter based option and an alternative to surgery in the treatment of patients…”
Get more information

754 What is the correct amount of ethanol in the catheter based treatment for hypertrophic obstructive cardiomyopathy? by LAWRENZ, T

Get full text

P2897 Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: studies of Infarction markers and alcohol spill over by LAWRENZ, T

Get full text

Outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a European multicentre and multinational study by Veselka, J., Lawrenz, T., Branny, M., Sitar, J., Dimitrow, P., Krejci, J., Dabrowski, M., Mizera, S., Bartel, T., Stellbrink, C.

Get full text

Transcoronary Ablation of Septal Hypertrophy Does Not Alter ICD Intervention Rates in High Risk Patients with Hypertrophic Obstructive Cardiomyopathy by LAWRENZ, THORSTEN, OBERGASSEL, LUDGER, LIEDER, FRANK, LEUNER, CHRISTIAN, STRUNK-MUELLER, CLAUDIA, MEYER, DOROTHEE, VILSENDORF, ZU, BEER, GERALD, KUHN, HORST

“…Introduction: Transcoronary ablation of septal hypertrophy (TASH) is safe and effectively reduces the intraventricular gradient in patients with hypertrophic…”
Get full text